UC San Diego School of Medicine

Mark conducted seminal research on the role of CD47 in cancer immune evasion and is a founder of Forty Seven, Inc., developing a first-in-class CD47 targeting antibody in cancer. Mark received his medical degree, Ph.D. in cancer … ................
................